If you have been reading about lyophilisation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
=== Limitation of structure databases === Structure databases are orders of magnitude larger than spectral libraries but still incomplete. It is understood that not every existing biomolecule is or will be contained in structure databases. For these instances, SIRIUS offers several solutions:
=== Pharmacodynamics === Benzodiazepine like compounds are acting as positive allosteric modulators to the gamma-aminobutyric acid GABAA receptor. GABA is the main inhibitor of neurotransmitters in the brain and modulates the activity of many neurons. Benzodiazepines bind to the GABAA receptor inducing a conformational change leading to an increased affinity to GABA. The allosteric binding site is situated in a "pocket" created by the alpha and gamma subunits. The pharmacological effects on benzodiazepines vary based on which alpha subunit of the GABAA receptor the benzodiazepine binds to. The sedative, anterograde amnesic, anticonvulsant actions, and the addictive nature of benzodiazepines, are due to the binding to the α1 subunit of the (GABA)A receptor. Binding to the α2 subunit will cause the anxiolytic effects, and binding to the α2, α3, and α5 subunits will lead to the myorelaxant effects. According to research done by the WHO bromazolam binds to the α1, α2, and α5 subunits.
== Interactions == CYP3A4 inhibitors can increase exposure to suvorexant while CYP3A4 inducers can decrease exposure to suvorexant. Combination of suvorexant with the strong CYP3A4 inhibitor ketoconazole increased suvorexant overall exposure by 2.79-fold and peak levels by about 1.25-fold, combination with the moderate CYP3A4 inhibitor diltiazem increased suvorexant overall exposure by 2.05-fold and peak levels by about 1.25-fold, and combination with the strong CYP3A4 inducer rifampin decreased suvorexant overall exposure by 88% and peak levels by about 65%. The elimination half-life of suvorexant (about 12 hours for suvorexant alone) was increased to 19.4 hours with ketoconazole and to 16.1 hours with diltiazem while it was decreased to 7.7 hours with rifampin. Concomitant use of suvorexant with strong CYP3A4 inhibitors is not recommended, while lower doses of suvorexant are recommended with moderate CYP3A4 inhibitors (5 mg starting dose and 10 mg maximum dose generally). The substantial decrease in suvorexant exposure with strong CYP3A4 inducers may result in loss of effectiveness. Suvorexant does not appear to have been assessed in combination with moderate CYP3A4 inducers (e.g., modafinil).
=== Radiological cleanup === A radiological survey of Enewetak was conducted from 1972 to 1973. In 1977, the United States military began decontamination of Enewetak and other islands. During the three-year, US$100 million cleanup process, the military mixed more than 80,000 cubic meters (100,000 cu yd) of contaminated soil and debris from the islands with Portland cement and buried it in an atomic blast crater on the northern end of the atoll's Runit Island. The material was placed in the 9.1-meter (30 ft) deep, 110-meter (360 ft) wide crater created by the May 5, 1958, "Cactus" nuclear weapons test. A dome composed of 358 concrete panels, each 46 centimeters (18 in) thick, was constructed over the material. The final cost of the cleanup project was US$239 million. The United States government declared the southern and western islands in the atoll safe for habitation in 1980, and residents of Enewetak returned that same year. The military members who participated in that cleanup mission are suffering from many health issues, but the U.S. Government refused to provide health coverage until 2022 with the passage of the Honoring our PACT Act. The 2000 environmental restoration award included funds for additional cleanup of radioactivity on Enewetak. Rather than scrape the topsoil off, replace it with clean topsoil, and create another radioactive waste repository dome at some site on the atoll (a project estimated to cost US$947 million), most areas still contaminated on Enewetak were treated with potassium.
ERAP1 can be secreted into the extracellular space in response to inflammatory stimuli, which can lead to the activation of immune cells, such as macrophages or natural killer cells, and enhanced expression of pro-inflammatory cytokines.
Sources: en.wikipedia.org
=== Neurotoxins === There is evidence that system Xc- may serve as an entry point for neurotoxins and viruses. β-N-methyl-L-alanine (BMAA) is an environmental neurotoxin that can act on system Xc- and inhibit cystine uptake. This leads to a decrease in glutathione levels and an increase in oxidative stress. BMAA can also be transported by system Xc- and lead to an increase in glutamate release and an increase in excitotoxicity. Therefore, BMAA prevents the positive effects of cystine uptake and creates the negative effects of increasing glutamate release.
Kennedy decided toward the end of 1871 to end his business partnership with Eddy. She had accused him in front of others of cheating at cards; it was one of several scenes she had caused between them and he walked out on her. There was a temporary reconciliation, but he was unhappy about the abandonment of head rubbing, and after a dispute between Eddy and a student over a refund was played out in the local press, he decided to go his own way. Once Kennedy and Eddy had settled their financial affairs in May 1872, she was left with $6,000. Peel writes that at this point she had already written 60 pages of Science and Health. She was renting rooms in Lynn at 9 Broad Street, when 8 Broad Street came on the market. In March 1875 she purchased it for $5,650, taking in students to pay the mortgage. It was in the attic room of this house that she completed Science and Health. Shortly after moving in, Eddy became close to another student, Daniel Spofford. He was 33 years old and married when he joined her class; he later left his wife in the hope that he might marry Eddy, but his feelings were not reciprocated. Spofford and seven other students agreed to form an association that would pay Eddy a certain amount a week if she would preach to them every Sunday. They called themselves the Christian Scientists' Association. Eddy placed a sign on 8 Broad Street: "Mary B.
The highest approval rating for the government was in the Northeast (65%), among people with up to a completed elementary education (60%), those earning two minimum wages (59%), and among women (59%). In a survey conducted by PoderData between 24 and 26 September with 2,500 people, a margin of error of 2 percentage points, and a confidence level of 95%, the government obtained 48% approval and 45% disapproval. The regions that most approve of the Lula government are the Southeast and the Northeast, and his government is more approved among younger and older poor and middle-class women. Lula as a person received 36% of mentions as excellent or good, 25% as regular, and 35% as bad or terrible. The survey also asked whether respondents liked Lula's administration more than Bolsonaro's. Forty-eight percent agreed with the statement, 40% disagreed, and 9% said there was no difference. Among evangelicals, government approval fell by two percentage points to 32%, and rejection rose to 64%. Among Catholics, approval fell by 3 percentage points to 57%, and disapproval rose to 36%. In a survey released by Paraná Pesquisas on 13 January 2025, it was revealed that the negative evaluation of President Luiz Inácio Lula da Silva's government exceeded the positive one. According to the survey data, 11.1% of Brazilians considered the government excellent and 22.7% classified it as good, totaling 33.8% positive evaluation. On the other hand, 42.6% of respondents evaluated the government as bad (8.4%) or terrible (34.2%).
== Medical uses == Mesocarb was originally developed in the Soviet Union in the 1970s for a variety of indications including asthenia, apathy, adynamia, and some clinical aspects of depression and schizophrenia. Mesocarb was used for counteracting the sedative effects of benzodiazepines, increasing workload capacity and cardiovascular function, treatment of attention deficit hyperactivity disorder (ADHD) in children, as a nootropic, and as a drug to enhance resistance to extremely cold temperatures. It has also been reported to have antidepressant and anticonvulsant properties.
The kinetics of labeled derivatives of apamin were studied in vitro and in vivo in mice by Cheng-Raude et al. This shed some light on the kinetics of apamin itself. The key organ for excretion is likely to be the kidney, since enrichment of the labeled derivatives was found there. The peptide apamin is small enough to pass the glomerular barrier, facilitating renal excretion. The central nervous system, contrarily, was found to contain only very small amounts of apamin. This is unexpected, as this is the target organ for neurotoxicity caused by apamin. This low concentration thus appeared to be sufficient to cause the toxic effects. However, these results disagree with a study of Vincent et al. After injection of a supralethal dose of radioactive acetylated apamin in mice, enrichment was found in the spinal cord, which is part of the target organ. Some other organs, including kidney and brain, contained only small amounts of the apamin derivative. Symptoms following bee sting may include:
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.